Overview

SCIENTIFIC SCORE
Possibly Effective
Based on 56 Researches
7.5
USERS' SCORE
Moderately Good
Based on 8 Reviews
7.7
Supplement Facts
Serving Size:  2 Capsules
Amount Per Serving
%DV
Mood Probiotic BlendLactobacillus acidophilusLactobacillus plantarumLactobacillus helveticus R0052Lactobacillus paracaseiLactobacillus caseiLactobacillus brevisLactobacillus rhamnosusLactobacillus bulgaricusLactobacillus gasseriLactobacillus salivariusTotal Lacto Cultures (45 Billion CFU)Bifidobacterium lactisBifidobacterium longum R0175Bifidobacterium bifidumBifidobacterium breveBifidobacterium infantisBifidobacterium longumTotal Bifido Cultures (5 Billion CFU)
200 mg
+
Total Probiotic Cultures
50 Billion CFU¹
 
Stress Support BlendOrganic Ashwagandha (root), Blueberry (fruit)
350 mg
+
Organic Prebiotic Fiber BlendOrganic Potato [Resistant Starch] (tuber), Organic Acacia Fiber (A. senegal)
675 mg
+

Top Medical Research Studies

9.5
Bifidobacterium bifidum improves IBS symptoms
We assessed how Bifidobacterium bifidum MIMBb75 impacts symptoms of irritable bowel syndrome (IBS) in a controlled study of 122 participants.

Over four weeks, those taking MIMBb75 reported significantly reduced IBS symptoms compared to the placebo group.

With many experiencing better pain relief and improved quality of life, these findings suggest that MIMBb75 could be a valuable treatment option for IBS, showing durability with minimal side effects.
Read More
9.5
CECT 7347 reduces IBS-D symptoms
A randomized, double-blind, placebo-controlled trial exploring CECT 7347 (ES1) and heat-treated CECT 7347 (HT-ES1) revealed promising results for diarrhea-predominant irritable bowel syndrome (IBS-D).

We found that after 12 weeks, both ES1 and HT-ES1 significantly reduced symptom severity compared to a placebo, as shown by lower IBS-Symptom Severity Scale scores.

Other improvements included better stool consistency and quality of life. This study marks a breakthrough with the first positive findings for a probiotic or postbiotic from this strain specifically for IBS-D patients.
Read More
9
Effective treatment for IBS-C
We aimed to understand how Lacticaseibacillus rhamnosus IDCC 3201 (RH 3201) affects irritable bowel syndrome with constipation (IBS-C) through a thorough study. In a randomized, double-blind trial, 30 participants took either RH 3201 or a placebo for 8 weeks.

Those taking RH 3201 experienced significant improvements, including fewer bowel discomforts and reduced bloating issues. We also observed an increase in certain beneficial gut bacteria and a link between specific metabolites and symptom relief. Overall, RH 3201 shows promise as an effective treatment for IBS-C.
Read More

Most Useful Reviews

7.5
Improved constipation
1 people found this helpful
The quality is good, the ingredients are sound, and the quantity is reasonable. After consulting my doctor, I feel it has improved my constipation and bowel movements significantly.
Read More
7.5
Elevates mood
1 people found this helpful
It worked for me. Other probiotics regulated my bowel dysfunction, but Mood+ notably lifted my spirits. I realised this when my local shop stopped carrying it, and I switched to another probiotic, missing the mood-enhancing benefits. I found it online again.
Read More
7.5
Adjusts mood
An excellent product that helps to balance mood, bowel movements, and colon health.
Read More

Medical Researches

SCIENTIFIC SCORE
Possibly Effective
Based on 56 Researches
7.5
  • All Researches
9.5
Effective probiotic IBS treatment
This randomized, single-blinded trial evaluated the impact of probiotics, specifically Lactobacillus acidophilus and plantarum, on patients with diarrhea-predominant irritable bowel syndrome (IBS-D).

We found that when added to standard IBS treatment, these probiotics significantly improved symptoms over a 12-week period.

Group B, the probiotic group, experienced better results, including fewer days with pain and greater satisfaction with bowel habits. While both groups saw reductions in IBS severity, the probiotics led to complete remission in many patients, which is promising for future treatment guidelines.
Read More
9.5
Effective probiotic IBS treatment
This randomized, single-blinded trial evaluated the impact of probiotics, specifically Lactobacillus acidophilus and plantarum, on patients with diarrhea-predominant irritable bowel syndrome (IBS-D).

We found that when added to standard IBS treatment, these probiotics significantly improved symptoms over a 12-week period.

Group B, the probiotic group, experienced better results, including fewer days with pain and greater satisfaction with bowel habits. While both groups saw reductions in IBS severity, the probiotics led to complete remission in many patients, which is promising for future treatment guidelines.
Read More
9.5
Bifidobacterium bifidum improves IBS symptoms
We assessed how Bifidobacterium bifidum MIMBb75 impacts symptoms of irritable bowel syndrome (IBS) in a controlled study of 122 participants.

Over four weeks, those taking MIMBb75 reported significantly reduced IBS symptoms compared to the placebo group.

With many experiencing better pain relief and improved quality of life, these findings suggest that MIMBb75 could be a valuable treatment option for IBS, showing durability with minimal side effects.
Read More
9.5
CECT 7347 reduces IBS-D symptoms
A randomized, double-blind, placebo-controlled trial exploring CECT 7347 (ES1) and heat-treated CECT 7347 (HT-ES1) revealed promising results for diarrhea-predominant irritable bowel syndrome (IBS-D).

We found that after 12 weeks, both ES1 and HT-ES1 significantly reduced symptom severity compared to a placebo, as shown by lower IBS-Symptom Severity Scale scores.

Other improvements included better stool consistency and quality of life. This study marks a breakthrough with the first positive findings for a probiotic or postbiotic from this strain specifically for IBS-D patients.
Read More
9
Lactobacillus drink benefits IBS-C
We explored the impact of a Lactobacillus-containing cultured milk drink on individuals with constipation-predominant irritable bowel syndrome (IBS-C). Over 30 days, participants consumed this drink daily while we assessed their clinical symptoms and inflammatory markers.

Impressively, 97.4% reported improvement in symptoms, along with noticeable reductions in intestinal transit time and fecal pH. Evidence also showed lowered levels of pro-inflammatory cytokines in IBS-C participants, supporting potential adjunctive benefits of this treatment for IBS-C patients.
Read More

User Reviews

USERS' SCORE
Moderately Good
Based on 8 Reviews
7.7
  • All Reviews
  • Positive Reviews
  • Negative Reviews
7.5
Improved constipation
1 people found this helpful
The quality is good, the ingredients are sound, and the quantity is reasonable. After consulting my doctor, I feel it has improved my constipation and bowel movements significantly.
Read More
7.5
Elevates mood
1 people found this helpful
It worked for me. Other probiotics regulated my bowel dysfunction, but Mood+ notably lifted my spirits. I realised this when my local shop stopped carrying it, and I switched to another probiotic, missing the mood-enhancing benefits. I found it online again.
Read More
7.5
Adjusts mood
An excellent product that helps to balance mood, bowel movements, and colon health.
Read More
6
Smooth bowel movements
High quality! I saw someone recommend a very professional brand online. While I don't have strong feelings about this aspect, my bowel movements have been smooth, and the capsules are easy to take. I can open the capsule, soak the powder in water, and it doesn't taste odd.
Read More
7.5
Improves mood
1 people found this helpful
If we have problems with the intestines, then we also face issues with the head. Therefore, probiotics enhance bowel function and help maintain a positive mood while minimising stress.
Read More

Frequently Asked Questions

7.5
Improved constipation
1 people found this helpful
The quality is good, the ingredients are sound, and the quantity is reasonable. After consulting my doctor, I feel it has improved my constipation and bowel movements significantly.
6
Smoother bowel movement
After two months of usage, I’ve seen improvements in my mood. It’s effective under work pressure and has made my bowel movements smoother.
7.5
Elevates mood
1 people found this helpful
It worked for me. Other probiotics regulated my bowel dysfunction, but Mood+ notably lifted my spirits. I realised this when my local shop stopped carrying it, and I switched to another probiotic, missing the mood-enhancing benefits. I found it online again.
7.5
Improves mood
1 people found this helpful
If we have problems with the intestines, then we also face issues with the head. Therefore, probiotics enhance bowel function and help maintain a positive mood while minimising stress.
6
Reduces anxiety
1 people found this helpful
A fantastic probiotic for regulating my bowels, but it also assists in reducing anxiety.
6
Helps digestion
It's a good one. It aids in addressing digestive and bowel issues even with just one capsule, half the recommended dose. I'd certainly purchase it again!
9.5
Effective probiotic IBS treatment
This randomized, single-blinded trial evaluated the impact of probiotics, specifically Lactobacillus acidophilus and plantarum, on patients with diarrhea-predominant irritable bowel syndrome (IBS-D).

We found that when added to standard IBS treatment, these probiotics significantly improved symptoms over a 12-week period.

Group B, the probiotic group, experienced better results, including fewer days with pain and greater satisfaction with bowel habits. While both groups saw reductions in IBS severity, the probiotics led to complete remission in many patients, which is promising for future treatment guidelines.
8
Probiotics help relieve IBS symptoms
We investigated the impact of multispecies probiotics, including Lactobacillus acidophilus, in treating irritable bowel syndrome (IBS). In a randomized, double-blind study with 49 participants, those taking probiotics experienced significantly more symptom relief than those on a placebo after four weeks.

The probiotics not only eased abdominal discomfort and bloating but also positively altered gut bacteria. Our findings suggest that multispecies probiotics could be a valuable option for managing IBS symptoms.
7
Probiotics modestly improve IBS
We examined the effects of a combination of Lactobacillus acidophilus CL1285 and other probiotics compared to a placebo in treating irritable bowel syndrome (IBS). Over 12 weeks, 113 participants reported significant improvements in abdominal pain, stool consistency, and overall quality of life.

Interestingly, those with diarrhea-predominant IBS and female participants noticed the most benefits. Though there were some mild adverse effects, serious issues were not reported. Overall, while some gains were observed, pain intensity and a few symptom relief measures did not show substantial improvement.
8
Probiotics show promise for IBS relief
We evaluated the efficacy of quadruple-coated probiotics in patients with irritable bowel syndrome (IBS). One hundred and nine participants were randomly assigned to either the probiotic or placebo group for four weeks.

Participants recorded their symptoms, and we noted a significant improvement in overall IBS symptoms, particularly in female and constipation-predominant patients. The results were promising, suggesting that these probiotics can provide relief. However, further studies are needed to explore why women respond differently to this treatment.

References

  1. Sarkawi M, Raja Ali RA, Abdul Wahab N, Abdul Rathi ND, Mokhtar NM. A randomized, double-blinded, placebo-controlled clinical trial on Lactobacillus-containing cultured milk drink as adjuvant therapy for depression in irritable bowel syndrome. Sci Rep. 2024;14:9478. doi:10.1038/s41598-024-60029-2
  2. Shanshal SA, Alsaaty MH, Al-Qazaz H, Al-Zidan RN. Two Lactobacilli strains as adjuvant therapy in the management of irritable bowel syndrome: a randomized control trial. Ceska Slov Farm. 2024;72:233.
  3. Shanshal SA, Alsaaty MH, Al-Qazaz H, Al-Zidan RN. Two Lactobacilli strains as adjuvant therapy in the management of irritable bowel syndrome: a randomized control trial. Ceska Slov Farm. 2024;73:233.
  4. Chang YH, Choi YJ, Shin CM, Moon JS, Kim TY, et al. Efficacy of Quadruple-coated Probiotics in Patients With Irritable Bowel Syndrome: A Randomized, Double-blind, Placebo-controlled, Parallel-group Study. J Neurogastroenterol Motil. 2024;30:73. doi:10.5056/jnm23036
  5. Drozdov VN, Shikh EV, Astapovskii AA, Khalaidzheva KN, Solovieva SA, et al. [Clinical efficacy of a modern probiotic for the correction of intestinal microflora in patients with irritable bowel syndrome with diarrhea and antibiotic-associated diarrhea]. Vopr Pitan. 2023;92:92. doi:10.33029/0042-8833-2023-92-4-92-103
  6. Cocetta V, Giacomini I, Tinazzi M, Berretta M, Quagliariello V, et al. Maintenance of intestinal epithelial barrier integrity by a combination of probiotics, herbal extract, and vitamins. Minerva Pediatr (Torino). 2023. doi:10.23736/S2724-5276.23.07128-8
  7. Shin SY, Park S, Moon JM, Kim K, Kim JW, et al. Compositional Changes in the Gut Microbiota of Responders and Non-responders to Probiotic Treatment Among Patients With Diarrhea-predominant Irritable Bowel Syndrome: A Post Hoc Analysis of a Randomized Clinical Trial. J Neurogastroenterol Motil. 2022;28:642. doi:10.5056/jnm21202
  8. Mokhtar NM, Jaafar NM, Alfian E, Mohd Rathi ND, Abdul Rani R, et al. Clinical assessment and cytokines level in constipation-predominant irritable bowel syndrome participants treated with Lactobacillus-containing cultured milk drink. Acta Gastroenterol Belg. 2021;84:585. doi:10.51821/84.4.009
  9. Skrzydło-Radomańska B, Prozorow-Król B, Cichoż-Lach H, Majsiak E, Bierła JB, et al. The Effectiveness of Synbiotic Preparation Containing and Probiotic Strains and Short Chain Fructooligosaccharides in Patients with Diarrhea Predominant Irritable Bowel Syndrome-A Randomized Double-Blind, Placebo-Controlled Study. Nutrients. 2020;12. doi:10.3390/nu12071999
  10. Martoni CJ, Srivastava S, Leyer GJ. DDS-1 and UABla-12 Improve Abdominal Pain Severity and Symptomology in Irritable Bowel Syndrome: Randomized Controlled Trial. Nutrients. 2020;12. doi:10.3390/nu12020363
  11. Sadrin S, Sennoune S, Gout B, Marque S, Moreau J, et al. A 2-strain mixture of Lactobacillus acidophilus in the treatment of irritable bowel syndrome: A placebo-controlled randomized clinical trial. Dig Liver Dis. 2020;52:534. doi:10.1016/j.dld.2019.12.009
  12. Preston K, Krumian R, Hattner J, de Montigny D, Stewart M, et al. Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R and Lactobacillus rhamnosus CLR2 improve quality-of-life and IBS symptoms: a double-blind, randomised, placebo-controlled study. Benef Microbes. 2018;9:697. doi:10.3920/BM2017.0105
  13. Leventogiannis K, Gkolfakis P, Spithakis G, Tsatali A, Pistiki A, et al. Effect of a Preparation of Four Probiotics on Symptoms of Patients with Irritable Bowel Syndrome: Association with Intestinal Bacterial Overgrowth. Probiotics Antimicrob Proteins. 2019;11:627. doi:10.1007/s12602-018-9401-3
  14. Bogovič Matijašić B, Obermajer T, Lipoglavšek L, Sernel T, Locatelli I, et al. Effects of synbiotic fermented milk containing Lactobacillus acidophilus La-5 and Bifidobacterium animalis ssp. lactis BB-12 on the fecal microbiota of adults with irritable bowel syndrome: A randomized double-blind, placebo-controlled trial. J Dairy Sci. 2016;99:5008. doi:10.3168/jds.2015-10743
  15. Yoon H, Park YS, Lee DH, Seo JG, Shin CM, et al. Effect of administering a multi-species probiotic mixture on the changes in fecal microbiota and symptoms of irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Clin Biochem Nutr. 2015;57:129. doi:10.3164/jcbn.15-14
  16. Yoon JS, Sohn W, Lee OY, Lee SP, Lee KN, et al. Effect of multispecies probiotics on irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Gastroenterol Hepatol. 2014;29:52. doi:10.1111/jgh.12322
  17. Barbaro MR, Bianco F, Cremon C, Marasco G, Stanghellini V, et al. A Probiotic Mixture of LR 32, BL 04, and BB 536 Counteracts the Increase in Permeability Induced by the Mucosal Mediators of Irritable Bowel Syndrome by Acting on Zonula Occludens 1. Int J Mol Sci. 2025;26. doi:10.3390/ijms26062656
  18. Gąsiorowska A, Romanowski M, Walecka-Kapica E, Kaczka A, Chojnacki C, et al. Efficacy and Safety of a Mixture of Microencapsulated Sodium Butyrate, Probiotics, and Short Chain Fructooligosaccharides in Patients with Irritable Bowel Syndrome-A Randomized, Double-Blind, Placebo-Controlled Study. J Clin Med. 2024;14. doi:10.3390/jcm14010006
  19. Kwon H, Nam EH, Kim H, Jo H, Bang WY, et al. Effect of Lacticaseibacillus rhamnosus IDCC 3201 on irritable bowel syndrome with constipation: a randomized, double-blind, and placebo-controlled trial. Sci Rep. 2024;14:22384. doi:10.1038/s41598-024-72887-x
  20. Zhang L, Ni X, Jiang M, Du M, Zhang S, et al. Strains for Alleviation of Irritable Bowel Disease and Chronic Fatigue Syndrome. Microorganisms. 2024;12. doi:10.3390/microorganisms12061081
  21. Bonfrate L, Di Palo DM, Celano G, Albert A, Vitellio P, et al. Effects of Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 in IBS patients. Eur J Clin Invest. 2020;50:e13201. doi:10.1111/eci.13201
  22. Ding FCL, Karkhaneh M, Zorzela L, Jou H, Vohra S. Probiotics for paediatric functional abdominal pain disorders: A rapid review. Paediatr Child Health. 2019;24:383. doi:10.1093/pch/pxz036
  23. Nocerino R, Di Costanzo M, Bedogni G, Cosenza L, Maddalena Y, et al. Dietary Treatment with Extensively Hydrolyzed Casein Formula Containing the Probiotic Lactobacillus rhamnosus GG Prevents the Occurrence of Functional Gastrointestinal Disorders in Children with Cow's Milk Allergy. J Pediatr. 2019;213:137. doi:10.1016/j.jpeds.2019.06.004
  24. Hojsak I. Probiotics in Functional Gastrointestinal Disorders. Adv Exp Med Biol. 2019;1125:121. doi:10.1007/5584_2018_321
  25. Han X, Lee A, Huang S, Gao J, Spence JR, et al. Lactobacillus rhamnosus GG prevents epithelial barrier dysfunction induced by interferon-gamma and fecal supernatants from irritable bowel syndrome patients in human intestinal enteroids and colonoids. Gut Microbes. 2019;10:59. doi:10.1080/19490976.2018.1479625
  26. Wegh CAM, Benninga MA, Tabbers MM. Effectiveness of Probiotics in Children With Functional Abdominal Pain Disorders and Functional Constipation: A Systematic Review. J Clin Gastroenterol. 2018;52 Suppl 1, Proceedings from the 9th Probiotics, Prebiotics and New Foods, Nutraceuticals and Botanicals for Nutrition & Human and Microbiota Health Meeting, held in Rome, Italy from September 10 to 12, 2017:S10. doi:10.1097/MCG.0000000000001054
  27. Darbaky Y, Evrard B, Patrier S, Falenta J, Garcin S, et al. Oral probiotic treatment of Lactobacillus rhamnosus Lcr35 prevents visceral hypersensitivity to a colonic inflammation and an acute psychological stress. J Appl Microbiol. 2017;122:188. doi:10.1111/jam.13320
  28. Cruchet S, Furnes R, Maruy A, Hebel E, Palacios J, et al. The use of probiotics in pediatric gastroenterology: a review of the literature and recommendations by Latin-American experts. Paediatr Drugs. 2015;17:199. doi:10.1007/s40272-015-0124-6
  29. Chung HG, Min YW, Lee C, Hong SN, Won JY, et al. Effects of Novel Probiotics in a Murine Model of Irritable Bowel Syndrome. Korean J Gastroenterol. 2020;75:141. doi:10.4166/kjg.2020.75.3.141
  30. Ruiz-Sánchez C, Escudero-López B, Fernández-Pachón MS. Evaluation of the efficacy of probiotics as treatment in irritable bowel syndrome. Endocrinol Diabetes Nutr (Engl Ed). 2024;71:19. doi:10.1016/j.endien.2024.01.003
  31. Tomita T, Fukui H, Okugawa T, Nakanishi T, Mieno M, et al. Effect of G9-1 on the Intestinal Environment and Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)-like Symptoms in Patients with Quiescent Crohn's Disease: A Prospective Pilot Study. J Clin Med. 2023;12. doi:10.3390/jcm12103368
  32. Andresen V, Gschossmann J, Layer P. Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial. Lancet Gastroenterol Hepatol. 2020;5:658. doi:10.1016/S2468-1253(20)30056-X
  33. Guglielmetti S, Mora D, Gschwender M, Popp K. Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life--a double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2011;33:1123. doi:10.1111/j.1365-2036.2011.04633.x
  34. Hong KS, Kang HW, Im JP, Ji GE, Kim SG, et al. Effect of probiotics on symptoms in korean adults with irritable bowel syndrome. Gut Liver. 2009;3:101. doi:10.5009/gnl.2009.3.2.101
  35. Williams EA, Stimpson J, Wang D, Plummer S, Garaiova I, et al. Clinical trial: a multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study. Aliment Pharmacol Ther. 2009;29:97. doi:10.1111/j.1365-2036.2008.03848.x
  36. Martin FP, Cominetti O, Berger B, Combremont S, Marquis J, et al. Metabolome-associated psychological comorbidities improvement in irritable bowel syndrome patients receiving a probiotic. Gut Microbes. 2024;16:2347715. doi:10.1080/19490976.2024.2347715
  37. Srivastava S, Basak U, Naghibi M, Vijayakumar V, Parihar R, et al. A randomized double-blind, placebo-controlled trial to evaluate the safety and efficacy of live CECT 7347 (ES1) and heat-treated CECT 7347 (HT-ES1) in participants with diarrhea-predominant irritable bowel syndrome. Gut Microbes. 2024;16:2338322. doi:10.1080/19490976.2024.2338322
  38. Lenoir M, Wienke J, Fardao-Beyler F, Roese N. An 8-Week Course of Bifidobacterium longum 35624 Is Associated with a Reduction in the Symptoms of Irritable Bowel Syndrome. Probiotics Antimicrob Proteins. 2025;17:315. doi:10.1007/s12602-023-10151-w
  39. Khoo XH, Chong CW, Talha AM, Philip K, Teh CS, et al. The impact of diet and ethnicity on gut microbiota variation in irritable bowel syndrome: A multi-center study. J Gastroenterol Hepatol. 2023;38:1259. doi:10.1111/jgh.16174
  40. Nakamura Y, Suzuki S, Murakami S, Nishimoto Y, Higashi K, et al. Integrated gut microbiome and metabolome analyses identified fecal biomarkers for bowel movement regulation by BB536 supplementation: A RCT. Comput Struct Biotechnol J. 2022;20:5847. doi:10.1016/j.csbj.2022.10.026
  41. Yakovenko EP, Strokova TV, Ivanov AN, Iakovenko AV, Gioeva IZ, et al. [The effectiveness of a probiotic containing Bifidobacterium longum BB-46 and Enterococcus faecium ENCfa-68 in the treatment of post-infectious irritable bowel syndrome. Prospective randomized comparative study]. Ter Arkh. 2022;94:180. doi:10.26442/00403660.2022.02.201368
  42. Groeger D, Murphy EF, Tan HTT, Larsen IS, O'Neill I, et al. Interactions between symptoms and psychological status in irritable bowel syndrome: An exploratory study of the impact of a probiotic combination. Neurogastroenterol Motil. 2023;35:e14477. doi:10.1111/nmo.14477
  43. Sabaté JM, Iglicki F. Effect of 35624 on disease severity and quality of life in patients with irritable bowel syndrome. World J Gastroenterol. 2022;28:732. doi:10.3748/wjg.v28.i7.732
  44. Di Pierro F, Pane M. Bifidobacterium longum W11: Uniqueness and individual or combined clinical use in association with rifaximin. Clin Nutr ESPEN. 2021;42:15. doi:10.1016/j.clnesp.2020.12.025
  45. Caviglia GP, Tucci A, Pellicano R, Fagoonee S, Rosso C, et al. Clinical Response and Changes of Cytokines and Zonulin Levels in Patients with Diarrhoea-Predominant Irritable Bowel Syndrome Treated with ES1 for 8 or 12 Weeks: A Preliminary Report. J Clin Med. 2020;9. doi:10.3390/jcm9082353
  46. Buhner S, Hahne H, Hartwig K, Li Q, Vignali S, et al. Protease signaling through protease activated receptor 1 mediate nerve activation by mucosal supernatants from irritable bowel syndrome but not from ulcerative colitis patients. PLoS One. 2018;13:e0193943. doi:10.1371/journal.pone.0193943
  47. JanssenDuijghuijsen L, van den Belt M, Rijnaarts I, Vos P, Guillemet D, et al. Acacia fiber or probiotic supplements to relieve gastrointestinal complaints in patients with constipation-predominant IBS: a 4-week randomized double-blinded placebo-controlled intervention trial. Eur J Nutr. 2024;63:1983. doi:10.1007/s00394-024-03398-8
  48. Skrzydło-Radomańska B, Prozorow-Król B, Kurzeja-Mirosław A, Cichoż-Lach H, Laskowska K, et al. The Efficacy and Safety of Single-Strain Probiotic Formulations Containing or in Adult Patients with Irritable Bowel Syndrome-A Randomized Double-Blind Placebo-Controlled Three-Arm Interventional Trial. J Clin Med. 2023;12. doi:10.3390/jcm12144838
  49. Boonma P, Shapiro JM, Hollister EB, Badu S, Wu Q, et al. Probiotic VSL#3 Treatment Reduces Colonic Permeability and Abdominal Pain Symptoms in Patients With Irritable Bowel Syndrome. Front Pain Res (Lausanne). 2021;2:691689. doi:10.3389/fpain.2021.691689
  50. Xu H, Ma C, Zhao F, Chen P, Liu Y, et al. Adjunctive treatment with probiotics partially alleviates symptoms and reduces inflammation in patients with irritable bowel syndrome. Eur J Nutr. 2021;60:2553. doi:10.1007/s00394-020-02437-4
  51. Szajewska H, Hojsak I. Health benefits of GG and subspecies BB-12 in children. Postgrad Med. 2020;132:441. doi:10.1080/00325481.2020.1731214
  52. Le Nevé B, Derrien M, Tap J, Brazeilles R, Cools Portier S, et al. Fasting breath H2 and gut microbiota metabolic potential are associated with the response to a fermented milk product in irritable bowel syndrome. PLoS One. 2019;14:e0214273. doi:10.1371/journal.pone.0214273
  53. Baştürk A, Artan R, Yılmaz A. Efficacy of synbiotic, probiotic, and prebiotic treatments for irritable bowel syndrome in children: A randomized controlled trial. Turk J Gastroenterol. 2016;27:439. doi:10.5152/tjg.2016.16301
  54. Eskesen D, Jespersen L, Michelsen B, Whorwell PJ, Müller-Lissner S, et al. Effect of the probiotic strain Bifidobacterium animalis subsp. lactis, BB-12®, on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial. Br J Nutr. 2015;114:1638. doi:10.1017/S0007114515003347
  55. Veiga P, Pons N, Agrawal A, Oozeer R, Guyonnet D, et al. Changes of the human gut microbiome induced by a fermented milk product. Sci Rep. 2014;4:6328. doi:10.1038/srep06328
  56. Barrett E, Fitzgerald P, Dinan TG, Cryan JF, Ross RP, et al. Bifidobacterium breve with α-linolenic acid and linoleic acid alters fatty acid metabolism in the maternal separation model of irritable bowel syndrome. PLoS One. 2012;7:e48159. doi:10.1371/journal.pone.0048159
image